Two medications for advanced squamous lung cancer after initial treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of two medications given after initial chemotherapy to keep advanced squamous lung cancer from growing. It might help patients whose cancer has not spread too much and who are generally in good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous non-small cell lung cancer that has spread (stage IV).
- Your PD-L1 score is less than 50%.
- You are generally able to take care of yourself and be up and about (ECOG 0 or 1).
- Your life expectancy is at least 6 months.
- You do not have significant immune system diseases or uncontrolled health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy and an anti-angiogenesis drug (rh-endostatin) for people with advanced or recurrent squamous non-small cell lung cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This study tests a new combination of drugs (SYHX2011, carboplatin, and an immunotherapy called enlonstobart) as the first treatment for advanced squamous lung cancer that is PD-L1 positive. The goal is to see if this combination helps shrink tumors and slow cancer growth.
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
This trial compares a new combination of drugs (one that targets cancer cells and another that boosts the immune system) against a standard chemotherapy plus immune therapy combination. The goal is to see if the new approach works better as a first treatment for advanced squamous lung cancer.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Hear when a new Squamous Non-Small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.